Managing patients with cutaneous squamous cell carcinoma metastatic to the axilla or groin lymph nodes

Abstract

Cutaneous squamous cell carcinoma accounts for 20% of all non-melanoma skin cancer with a minority arising on the trunk and extremities. A small proportion will develop metastases to regional nodes of the axilla or groin. We performed a retrospective review of patients with metastatic cutaneous squamous cell carcinoma to the axilla and groin treated at Westmead Hospital, Sydney. The purpose of this study was to document the treatment and outcome of these patients. We identified 18 men and 8 women with a median age of 73 years. Median follow-up was 18.5 months. Median lesion size was 27 mm (range 3-130 mm) and median thickness was 7 mm (range 3-32 mm). Nine patients developed metastases to the groin, 14 to the axilla, 1 in the epitrochlear, and 2 to both the epitrochlear and axillary lymph nodes. All patients were treated with surgery +/- radiotherapy. Recurrence developed in seven patients (27%) with most developing distant metastases. Most (6/7) patients with recurrence died. Predicting patients that may develop nodal metastatic non-head and neck cutaneous squamous cell carcinoma is difficult. Following diagnosis, surgery remains the primary treatment and select patients with unfavourable features, such as extranodal spread, may benefit from the addition of adjuvant radiotherapy.

Metastatic Cutaneous Squamous Cell Carcinoma to the Axilla: A Review of Patient Outcomes and Implications for Future Practice

“…A recent Australian series including axilla and inguinal cSCC metastases treated by surgery (n = 13) or surgery and radiotherapy (n = 13 median dose 50Gy) reported a crude relapse rate of 38% in irradiated patients with a median follow up of 18.5 months. The rate of local (nodal basin) recurrence was not specified but half of relapses were lung as the first site [ 19 ].…”

Outcomes of patients with metastatic cutaneous squamous cell carcinoma to the axilla: a multicentre cohort study

“…excision of the primary tumour with parotidectomy and/or neck dissection) or surgery‐plus‐adjuvant radiotherapy, with recurrence rates that range from 20% to 35% and 5‐year disease‐free survival (DFS) from 59% to 83% 8 . In contrast, there are limited data to guide the management of patients with metastatic cSCC to the axilla, with only five studies published in the past 15 years 9–13 …”

Clinical significance and epidemiological evolution of epitrochlear lymphadenopathy in pre- and post-highly active antiretroviral therapy era: A systematic review of the literature

“…We identified 144 articles, of which 79 (including 507 subjects) were found to be eligible for inclusion. [ 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 ] Infections ( n = 356, 70.2%) and neoplasms ( n = 116, 22.9%) were the most common reported cau...…”